Literature DB >> 18642357

Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.

Ted M Burns1, Mark R Conaway, Gary R Cutter, Donald B Sanders.   

Abstract

We describe the process whereby a recently developed myasthenia gravis (MG)-specific quality-of-life (QOL) instrument was reduced from 60 items to 15 items while maintaining potential usefulness in the clinic and in prospective treatment trials. In data from a recently completed prospective trial of mycophenolate mofetil (MMF) in MG, the MG-QOL15 correlated as highly as the 60-item MG-QOL for physical and social domains of the 36-item health survey of the Medical Outcomes Study Short Form (SF-36). Correlation coefficients for the MG-QOL15 were similar to the 60-item MG-QOL for the Quantitative Myasthenia Gravis (QMG), MG-specific Manual Muscle Testing (MG-MMT), and the MG-specific Activities of Daily Living (MG-ADL) scores at week 0 and for change in scores from week 0 to week 12 in the MMF trial. Using the physician global impression at week 12 of the trial as the "gold standard," the MG-QOL15 demonstrated high sensitivity. Because the MG-QOL15 instrument can be quickly and easily administered and interpreted, it is a potential QOL measure for treatment trials and the clinical evaluation of patients with MG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18642357     DOI: 10.1002/mus.21053

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  38 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

3.  Psychosocial aspects in myasthenic patients treated by plasmapheresis.

Authors:  Yu-Tai Chen; Yuanmay Chang; Hou-Chang Chiu; Jiann-Horng Yeh
Journal:  J Neurol       Date:  2011-02-02       Impact factor: 4.849

4.  Evaluation of a scale of patient-reported outcomes for the assessment of myasthenia gravis patients in China.

Authors:  Feng-bin Liu; Xin-lin Chen; Li Guo; Xiao-bin Liu
Journal:  Chin J Integr Med       Date:  2012-02-27       Impact factor: 1.978

5.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

6.  Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.

Authors:  John S Yi; Emily C Decroos; Donald B Sanders; Kent J Weinhold; Jeffrey T Guptill
Journal:  Muscle Nerve       Date:  2013-10-07       Impact factor: 3.217

7.  The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study.

Authors:  Matilde Leonardi; Alberto Raggi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  J Neurol       Date:  2009-08-08       Impact factor: 4.849

8.  Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes.

Authors:  Alberto Raggi; Matilde Leonardi; Renato Mantegazza; Silvia Casale; Giulia Fioravanti
Journal:  Neurol Sci       Date:  2010-04       Impact factor: 3.307

9.  Validation of the MG-DIS: a disability assessment for myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Silvia Schiavolin; Carlo Antozzi; Greta Brenna; Lorenzo Maggi; Renato Mantegazza
Journal:  J Neurol       Date:  2016-03-01       Impact factor: 4.849

10.  Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  Neurol Sci       Date:  2009-10-09       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.